Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007)

Diagnostic Microbiology and Infectious Disease

Volumn 64, Issue 2, 2009, Pages 177-184

  Biedenbach, Douglas J ^a   Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dalbavancin; DECIDE; Europe; Surveillance

Indexed keywords

ANTIINFECTIVE AGENT; CEFOXITIN; CEFTRIAXONE; CLINDAMYCIN; DALBAVANCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; METICILLIN; OXACILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; COAGULASE NEGATIVE STAPHYLOCOCCUS; FEMALE; GRAM POSITIVE BACTERIUM; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; EUROPE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; TEICOPLANIN; VANCOMYCIN; YOUNG ADULT;

EID: 67349140660     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.12.019     Document Type: Article

References (31)

1. Biedenbach D.J., Toleman M.A., Walsh T.R., and Jones R.N. Characterization of fluoroquinolone-resistant β-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). Diagn. Microbiol. Infect. Dis. 55 (2006) 119-127
2. Biedenbach D.J., Ross J.E., Fritsche T.R., Sader H.S., and Jones R.N. Activity of dalbavancin tested against Staphylococcus spp. and β-haemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J. Clin. Microbiol. 45 (2007) 998-1004
3. Boucher H.W., and Corey G.R. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46 Suppl 5 (2008) S344-S349
4. Bowker K.E., Noel A.R., and Macgowan A.P. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J. Antimicrob. Chemother. 58 (2006) 802-805
5. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests; approved standard-ninth edition, M2-A9 (2006), CLSI, Wayne, PA
6. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, 18th informational supplement, M100-S18 (2008), CLSI, Wayne, PA
7. Cuevas O., Cercenado E., Bouza E., Castellares C., Trincado P., Cabrera R., and Vindel A. Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Spain: a multicentre prevalence study (2002). Clin. Microbiol. Infect. 13 (2007) 250-256
8. Dauwalder O., Lina G., Durand G., Bes M., Meugnier H., Jarlier V., Coignard B., Vandenesch F., Etienne J., and Laurent F. Epidemiology of invasive methicillin-resistant Staphylococcus aureus clones collected in France in 2006 and 2007. J. Clin. Microbiol. 46 (2008) 3454-3458
9. Deurenberg R., Vink C., Kalenic S., Friedrich A., Bruggeman C., and Stobberingh E. The molecular evolution of methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 13 (2007) 222-235
10. Eisenstein B.I. Treatment challenges in the management of complicated skin and soft-tissue infections. Clin. Microbiol. Infect. 14 Suppl 2 (2008) 17-25
11. Enright M.C., Robinson D.A., Randle G., Feil E.J., Grundmann H., and Spratt B.G. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 7687-7692
12. Ergin A., Ercis S., and Hascelik G. In vitro susceptibility, tolerance and MLS resistance phenotypes of group C and group G streptococci isolated in Turkey between 1995 and 2002. Int. J. Antimicrob. Agents 22 (2003) 160-163
13. Graber C.J., Wong M.K., Carleton H.A., Perdreau-Remington F., Haller B.L., and Chambers H.F. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg. Infect. Dis. 13 (2007) 491-493
14. Hanslik T., Hartig C., Jurand C., Armand-Lefevre L., Jubault V., Rouveix E., Dubourg O., Prinseau J., Baglin A., and Nicolas-Chanoine M.H. Clinical significance of tolerant strains of streptococci in adults with infective endocarditis. Clin. Microbiol. Infect. 9 (2003) 852-857
15. Jauregui L.E., Babazadeh S., Seltzer E., Goldberg L., Krievins D., Frederick M., Krause D., Satilovs I., Endzinas Z., Breaux J., and O'Riordan W. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 41 (2005) 1407-1415
16. Jones R.N. Key considerations in the treatment of complicated staphylococcal infections. Clin. Microbiol. Infect. 14 Suppl 2 (2008) 3-9
17. Jones R.N., Fritsche T.R., Sader H.S., and Goldstein B.P. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J. Chemother. 17 (2005) 593-600
18. Jones R.N., Stilwell M.G., Sader H.S., Fritsche T.R., and Goldstein B.P. Spectrum and potency of dalbavancin tested against 3,322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn. Microbiol. Infect. Dis. 54 (2006) 149-153
19. Lin S.W., Carver P.L., and DePestel D.D. Dalbavancin: a new option for the treatment of Gram-positive infections. Ann. Pharmacother. 40 (2006) 449-460
20. Lina G., Piemont Y., Godail-Gamot F., Bes M., Peter M.O., Gauduchon V., Vandenesch F., and Etienne J. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis. 29 (1999) 1128-1132
21. Liu C., and Chambers H.F. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47 (2003) 3040-3045
22. Lopez S., Hackbarth C., Romano G., Trias J., Jabes D., and Goldstein B.P. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J. Antimicrob. Chemother. 55 Suppl 2 (2005) ii21-ii24
23. Moet G.J., Jones R.N., Biedenbach D.J., Stilwell M.G., and Fritsche T.R. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn. Microbiol. Infect. Dis. 57 (2007) 7-13
24. Perez-Roth E., Lorenzo-Diaz F., Batista N., Moreno A., and Mendez-Alvarez S. Tracking methicillin-resistant Staphylococcus aureus clones during a 5-year period (1998 to 2002) in a Spanish hospital. J. Clin. Microbiol. 42 (2004) 4649-4656
25. Pope S.D., and Roecker A.M. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy 26 (2006) 908-918
26. Seltzer E., Dorr M.B., Goldstein B.P., Perry M., Dowell J.A., and Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 37 (2003) 1298-1303
27. Streit J.M., Fritsche T.R., Sader H.S., and Jones R.N. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. 48 (2004) 137-143
28. Streit J.M., Sader H.S., Fritsche T.R., and Jones R.N. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn. Microbiol. Infect. Dis. 53 (2005) 307-310
29. Stryjewski M.E., and Chambers H.F. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46 Suppl 5 (2008) S368-S377
30. Tenover F.C., McDougal L.K., Goering R.V., Killgore G., Projan S.J., Patel J.B., and Dunman P.M. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J. Clin. Microbiol. 44 (2006) 108-118
31. Zaoutis T., Schneider B., Steele Moore L., and Klein J.D. Antibiotic susceptibilities of group C and group G streptococci isolated from patients with invasive infections: evidence of vancomycin tolerance among group G serotypes. J. Clin. Microbiol. 37 (1999) 3380-3383